MDR, you seem to be very knowledgeable about SYN. I agree with you data should be released by yearend as promised by CEO. Do you know of the current status of Trimesta? It seems there should be news on its trial for cognitive functioning on MS patients. Trimesta is still SYN's most advanced stage drug, so any good news should be significant for share price uplifting.
If one reviews all the partners this co has been able to develop including the recent one with Yale, the validation for its technology is there. Yes, it hasn't had much revenue and earnings to talk about, but so are many biotechs which are trading multiple times of this co. I believe this is a worthwhile co to put some of your fund earmarked for speculative stocks. Definitely NOT to sell your house and put your proceeds in it, but some money you can put aside for a year or so without missing it is the way to go.
Do you know if these warrantswere exercised or expired worthless? Either way will be positive without these warrants hanging over. It does look like there was attempt to keep the share price under the exercised price, at least close to it enough, to render them expiring worthless.
One aspect you conveniently ignored is that SYN is one of R. Kirk's channel partners and he owns a controlling interest in this co. With the technology transfer from Kirk's XON, there is clear probability for its success. Kirk is one of the most astute biotech investors and his success lies in his ability to identify cutting edge small cos for investment. I'll invest along with him anytime. We'll have at least two topline reads on trials by the end of the year as promised by CEO Riley.
We'll see where SYN will be trading at in January!
This is why SYN hopefully will ink a partnership or even outright buy out by a large pharma with more influence and credibility to push Trimesta for FDA approval and marketing thereafter.
If you recall CBI went down big time due to this hedge fund manager, who is known shorting stocks, wrote a multiple page report raising questions on its accounting in taking over Shaw. CBI finally proved itself on the right course by earnings, revenue and many contract wins with a very large backlog of work. Of course GS saw an opportunity again to short the stock or helping the shorts by issuing downgrade despite the proven operations. You have lemmings following such suggestions to sell. This is the reason money is always made by financial institutions at the expense of small uninformed investors. SEC is never in the position to protect small investors because those work at SEC, particularly top administrators practically all came from the industry where they go back after their stint at SEC. We just have to learn such practices and do our DD and invest on our own conviction. CBI will return to much higher in a couple weeks when these shorts have covered and go long.
This management can't get its act together. May be SPCB should have bought it. SPCB CEO really know what he is doing and the stock has tripled since it bought the ID division from OTIV and has made it profitable.
Anyone either holding or considering buying "bargains" in this co should go to read the bankruptcy paper just filed by DNDN which actually does have a product, albeit mismanaged by the management, particularly the CEO whole sold a lot shares when it was at $50. AEZS has not only been mismanaged, but can't even develop any approvable product. Many years ago when KERX returned its drug that was being tested was a sign there was a lot pf problems with this co. KERX went on to have trials of its own drug and is now at $17. At the time it stopped the partnership, both KERX and AEZS were traded similarly at around $3. My mistake was to stay with AEZS without selling the shares and reinvested in KERX. At least I am glad I was out early part of the year to minimized my loss in comparison with the current price. THIS IS NO BARGAIN PRICED stock IMO.
ORB has an excellent reputation for what they do, so this setback is not going to derail the merger in any way IMO. If there is no adverse impact on the merger plan, it means the share price should gradually move back up. I thought the way the co handles the incident is masterful without avoiding responsibility with a plan to move back on track. This is the kind of management one can have confidence in. Just added to my position taking advantage of the price weakness today.
If you are in all Kirk's companies, do you own SYN? Look like today's loss in SYN, one of his cos, totally offsets gains in ZIOP! May be the best way to invest in Kirk is to invest in ZON which will benefit from success of all these small and diversified cos, while individual failure won't affect much your investment. Of course I don't mean SYN will not succeed, rather it is one of the Kirk's cos with the biggest potential, IMO.
Actually to your question, I believe this boyish guy will settle for a chevy over a Benz, not because unwillingness to wait, but he just can't afford a high priced product. This is why these people play shorts which is like margin play without having to have real capital to really invest in the market. Arguing with these people is futile.
If stock market acts according to text, then everybody makes money and you know it is not so. QE3, as you are so worried about its ending which, the pundits say, will lead to a stock market crash! It is simply not that easy. The more people worry about the market, the better it will perform. Like what Buffett has said "be greedy when everybody is fearful and be fearful, when everybody is greedy". This is the very reason many hedge funds will fold because they tried to outsmart the market and gave dire predictions and shorted the market. Other than a few smart ones that also long the market, many short hedgies have lost billions. While keeping some cash as dry powder for opportunities is prudent, but to sell all your positions for fear of a market crash is a totally wrong way to invest. Just look at the few suggested stocks I mentioned yesterday, one has already jumped 10% today. Listen to me and act accordingly will make you money. All such suggestions come free as well! The reason for most investors to lose money is they listen too much of the WS pundits whose interest is with their own financial institutions and large clients.
These people are not even honest. When I said insiders' selling regularly and relentlessly, I meant those management from CEO to CFO etc. Only one senior manager hasn't participate in such so-called automatic selling with the price set at, I think, at $10! They have their secondary offering at $22 and immediately increase the share size, so that they will have enough to give management free option shares. Like you I have a large position and is under water. The management is paid well. The CEO's compensation is over 1 million and he sold I believe 8000 shares EVERY month! How much he needs for his life style? I won't even mind if there is something substantially developed for new drug application. So far none. If management is willing to sell regularly at $10, that means they collectively value the share price at that level. Small wonder SGMO has been struggling ever since the secondary offering despite the partnership with BIIB. One of my most disappointment biotech holdings.
I agree this is a speculative trade, like most of the stocks for those posting here.
I accept the fact there will be winners and losers. As long as one doesn't use margin and has no immediate need for the money, you can reap/harvest gains and wait for losers become winners. In a bull market like this one, despite the occasional scary dips which actually gave one opportunity to buy, one always has more gainers to offset a few losers. Go short in this environment is for trouble you don't need. DDD is a profitable company, unlike AMZN, so it will bounce back soon enough. They just couldn't push it down under $36, so the low is set. This will go back over $40 in a week. A piece of advice to shorts, try to go long and buy SYN and ZIOP which are cheap stocks fitting your appetite. You'll thank me in a month. For those of you with more resources, but FB, TWTR, GILD and FEYE..
With seemingly positive earnings report and plenty cash at hand, this stock can't break $12! This is really a broken stock and I attribite the failing to the insiders' selling of stock practically at any price. Look like most of the investors lost money but the management team make out good and can reload their free option shares and turn around and sell them. Disgusting. This is why we need activist fund managers to get in and force the management/board to be more shareholders friendly, not self-serving treating the co as their piggy bank.
"This entire market is going to crash soon". Really? Those hedge funds that had predicted the same merely a few weeks ago are big losers now with quite a few may go belly up by the end of the year. I am glad you are in that camp. I bought a lot stocks during the recent period of dire predictions and am happy to see how these stocks have worked out these days. DDD is a different story. It is still a profitable company so it should do okay longer term. On top of it, some companies, such as HPQ, may even boy it instead of developing its own 3 D capability. Longs may suffer now, but there is a lot to like at these low prices.
I like your interpretation of the data read. Hopefully you are on the mark. The share price has come down quite a bit despite the market turning up big time in the past few sessions. So it seems the market is not reading it as a positive. Another factor for the downward pressure may indicate anxiety on potentially another secondary offering as the co had to cut back on the size of the IPO without sufficient funds raised. With that hanging over the stock, it may not move up short time unless some positive news. I simply put it aside waiting for it to turn positive.
Most small biotech cos were killed. People putting money back to the market after the sell-off generally buy large established co, such as GILD or CELG. It will take a while for small ones being considered unless there is some potential immediate development. If you want those co, take a look at INO with its Ebola and MS play and SYN which is an infectious disease play as well as for other indications.
I believe the market is reacting to the PI data today on the 11 patients. It said 7 of the 11 patients left the trial due to disease progression. If that's the case, that meant the drug wasn't working too well, right? However the co also mentioned most with clinical activities from the drug. Not sure how to interpret it. This is a small co partnered with CELG, so may be there is something positive for the future. Don't forget this one came IPO not long ago and the small number of shares were picked up by insiders as well as CELG at $10. I'll simply stay put on this one. With such small float, any move, up or down, is exaggerated.
If this deal doesn't work out, SGPG will receive 1 billion dollars for break-up fee. Windfall money for the co. Additional, this take-over attempt put SHIG in play for other large pharmas. All in all, either way will be positive in my opinion.